Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $58 | $50 | $0 | $50 |
| Gross Profit | -$58 | -$50 | $0 | -$50 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,389 | $5,598 | $6,874 | $6,096 |
| G&A Expenses | $0 | $2,518 | -$199 | $2,593 |
| SG&A Expenses | $3,522 | $3,378 | -$199 | $2,593 |
| Sales & Mktg Exp. | $0 | $860 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,912 | $8,976 | $6,527 | $8,884 |
| Operating Income | -$8,969 | -$9,027 | -$6,349 | -$8,624 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $665 | $2,875 | $2,034 | $2,372 |
| Pre-Tax Income | -$8,304 | -$8,296 | -$4,315 | -$6,548 |
| Tax Expense | -$7 | $7 | -$291 | $199 |
| Net Income | -$8,219 | -$8,150 | -$4,096 | -$6,314 |
| % Margin | – | – | – | – |
| EPS | -0.23 | -0.28 | -0.155 | -0.25 |
| % Growth | 17.9% | -80.6% | 38% | – |
| EPS Diluted | -0.23 | -0.28 | -0.155 | -0.25 |
| Weighted Avg Shares Out | 35,623 | 28,813 | 26,480 | 25,524 |
| Weighted Avg Shares Out Dil | 35,623 | 28,813 | 26,480 | 25,524 |
| Supplemental Information | – | – | – | – |
| Interest Income | $549 | $236 | $178 | $261 |
| Interest Expense | $386 | $321 | -$73 | $433 |
| Depreciation & Amortization | $58 | $50 | $8 | $50 |
| EBITDA | -$8,912 | -$8,029 | -$4,453 | -$8,574 |
| % Margin | – | – | – | – |